Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
This study has been completed.
Study NCT00062478   Information provided by BioNumerik Pharmaceuticals, Inc.

First Received on June 6, 2003.   Last Updated on April 1, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Brain Neoplasms
Malignant Neoplasms, Brain
Brain Tumors
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Interventions listed in this trial
Karenitecin (BNP1350)
Additional drug interventions recognized in this trial
Camptothecin
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Sponsors listed in this trial
BioNumerik Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services